SCHEMBL6927951

SCHEMBL6927951

Clc1cccc(Oc2ccccc2CC2CCNCC2)c1

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 10/20 0.63
SLC6A2 P23975 7/20 0.63
SLC6A3 Q01959 7/20 0.63
HTR1A P08908 4/20 0.63
HTR2C P28335 2/20 0.50
HTR2B P41595 2/20 0.50
HTR6 P50406 1/20 0.47
ACP1 P24666 1/20 0.45
RHEB Q15382 2/20 0.45
CYP2D6 P10635 1/20 0.42
HTR2A P28223 1/20 0.41
KCNH2 Q12809 1/20 0.41
GBA1 P04062 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7526768 0.85 SLC6A4 (0.56) SLC6A4SLC6A2SLC6A3HTR1ACYP2D6
SCHEMBL6925825 0.85 SLC6A4 (0.46) SLC6A4SLC6A2SLC6A3HTR1AHTR6
SCHEMBL1405196 0.85 SLC6A4 (0.63) SLC6A4SLC6A2SLC6A3HTR1AHTR6
SCHEMBL6922684 0.85 SLC6A4 (0.53) SLC6A4SLC6A2SLC6A3HTR1ACYP2D6
SCHEMBL6930121 0.85 SLC6A4 (0.44) SLC6A4SLC6A2SLC6A3HTR1AKCNH2
SCHEMBL6927385 0.83 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3HTR1AHTR2C
SCHEMBL6927183 0.82 SLC6A4 (0.44) SLC6A4SLC6A2SLC6A3HTR1AHTR6
SCHEMBL1155798 0.82 SLC6A2 (0.44) SLC6A4SLC6A2SLC6A3HTR1AHTR2C
Sulfuric Acid SCHEMBL1405530 0.81 SLC6A4 (0.56) SLC6A4SLC6A2SLC6A3HTR1AHTR6
SCHEMBL6929202 0.80 HTR2C (0.52) SLC6A4SLC6A2SLC6A3HTR1AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6518284-B2 For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) 2003-02-11 US claimed
US-20020038031-A1 New 4 - substituted piperidines ORJALES VENERO AURELIO (ES) 2002-03-28 US claimed
EP-1002794-A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) 2000-05-24 EP claimed
US-6518284-B2 For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) 2003-02-11 US disclosed
US-20020038031-A1 New 4 - substituted piperidines ORJALES VENERO AURELIO (ES) 2002-03-28 US disclosed
EP-1002794-A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) 2000-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038031-A1 New 4 - substituted piperidines ADRA2C, ADRB2, ADRB1 SLC6A4 11/4885SLC6A2 12/4885SLC6A3 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.